LYR-210 for Chronic Rhinosinusitis
Our lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS).
Lyra’s lead product candidate, entering Phase 2, is LYR-210 for chronic rhinosinusitis (CRS), an inflammatory disease of the nasal passages. LYR-210 is a proprietary therapeutic that uses Lyra’s transmucosal therapeutic system to deliver a custom long-acting formulation of mometasone fuorate, a proven steroid, deep into the sinonasal tissue.
LYR-210’s unique therapeutic properties enable it to address the challenges of CRS. Clinical results evaluating LYR-210 in CRS patients have shown LYR-210 to be safe and well-tolerated and demonstrated significant improvements in clinical outcomes in patients with CRS.
LYR-210 has the potential to be one of the first approved drug products for CRS and is the only product in development offering six months of continuous drug therapy with a single administration.
Douglas RG, Psaltis AJ, Rimmer J, Kuruvilla T, Cervin A, and Kuang Y. Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis International Forum of Allergy & Rhinology, Vol. 9, No. 4, April 2019.